Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2013 Fourth Quarter Financial and Year-End Business Results
Date:12/10/2013

ALISO VIEJO, Calif., Dec. 10, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and twelve-months ended September 30, 2013.

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

Quarterly Financial Highlights

  • Total company net revenues of $21.7 million
  • Gross and net NUEDEXTA® sales increased to $27.7 million and $20.2 million respectively
  • Cash, cash equivalents, and restricted investments of $57.5 million as of September 30, 2013
  • "2013 has been a break-out year for Avanir," said Keith A. Katkin, president and CEO of Avanir. "We have achieved a number of important and transformational milestones. In addition to robust growth of NUEDEXTA for PBA, we formed a co-promote partnership with Merck which will leverage our commercial leadership in the institutional setting. We also in-licensed a new investigational migraine treatment, gained European approval for NUEDEXTA and initiated a new phase II study of AVP-923 exploring its potential application in levadopa-induced dyskinesias in Parkinson's disease."

    Fiscal 2013 Fourth Quarter Results

  • Total net revenues for the quarter ended September 30, 2013 were $21.7 million, compared with $13.5 million for the comparable quarter in fiscal 2012, representing approximately 61% year-over-year growth. Total net revenues consist of NUEDEXTA net revenue and royalty revenue from Abreva®.
  • Total operating expenses were $36.2 million in the fourth quarter of fiscal 2013, excluding a one-time payment of $20.0 million related to AVP-825, compared with $24.2 million in the comparable period in fiscal 2012.
  • Cash used in operations was $10.1 million, excluding a one-time payment of $20.0 million related to AVP-825.
  • Ne
    '/>"/>

  • SOURCE Avanir Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Avanir Pharmaceuticals To Present at Three Conferences In May
    2. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Second Quarter Financial Results And Conference Call
    3. Avanir Pharmaceuticals to Present at Jefferies 2012 Global Healthcare Conference
    4. Avanir Pharmaceuticals Announces Date Of Fiscal 2012 Third Quarter Financial Results And Conference Call
    5. Avanir Pharmaceuticals To Present At Two Investor Conferences In August
    6. Avanir Pharmaceuticals Announces Enrollment Of First Patient In Study Of AVP-923 For The Treatment Of Agitation In Patients With Alzheimers Disease
    7. Avanir Pharmaceuticals Announces Publication Of PBA Burden Of Illness Study
    8. Avanir Pharmaceuticals To Present At UBS Global Life Sciences Conference
    9. Avanir Pharmaceuticals Achieves Commercial Milestones & Provides Clinical Updates
    10. Avanir Pharmaceuticals To Present At 24th Annual Piper Jaffray Healthcare Conference
    11. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014 Tegra Medical is very ... King as its new Chief Executive Officer.  Mark was ... which he has overseen the company,s four facilities in ... Costa Rica.  Mr. King joined Tegra Medical in 2012 with ...
    (Date:1/15/2014)... TORONTO , Jan. 15, 2014  According to ... medical technology market intelligence, the United ... occlusion (TEO) device markets will expand moderately through ... fastest-growing segments. In particular, increasing interest in drug-eluting ...
    (Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Global Markets ... -- Focus on End Users ... A drug delivery system is ...
    Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
    (Date:4/22/2014)... This news release is available in German . ... species are important intracellular signaling molecules, but their mode ... key aspects of cellular function and behavior, while at ... organelles, membranes and DNA. To analyze how redox signaling ... innovative optical microscopy technique has been developed jointly by ...
    (Date:4/22/2014)... 7 in 10 Americans support mandated coverage of birth ... researchers at the University of Michigan Health System. , ... of 18 at home, and adults with private or ... to support universal coverage of birth control medications, according ... of the American Medical Association ( JAMA ). ...
    (Date:4/22/2014)... alfa (trade name: NovoEight) has been approved since November ... patients with haemophilia A. In an early benefit assessment ... Market for Medicinal Products" (AMNOG), the German Institute for ... this new active ingredient offers an added benefit over ... findings, an added benefit of turoctocog alfa is not ...
    (Date:4/22/2014)... Cedars-Sinai stroke intervention researchers have been informed that ... of the National Institutes of Health, will award an ... clinical trial of an experimental drug for stroke. ... with recombinant tissue plasminogen activator, or rtPA the ... after onset. In laboratory rodent studies, 3K3A-APC, used in ...
    (Date:4/22/2014)... have found that the anxiety experienced with a ... impact a woman,s overall well-being. Their findings are ... was published online in the April 21, 2014 ... 40 to 60 percent of women who undergo ... experience a false-positive mammogram. Such mammograms require additional ...
    Breaking Medicine News(10 mins):Health News:Neuroimaging: Live from inside the cell 2Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 3Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 3Health News:False-positive mammogram anxiety has limited impact on women's well-being 2
    ... cholesterol-lowering statins were significantly less likely to develop depression than ... MD, a physician at the San Francisco VA Medical Center ... San Francisco. The study was published electronically in the ... Whooley and her research team evaluated 965 heart disease patients ...
    ... News) -- Many young children from low-income families drink too ... and tooth decay, the American Academy of Pediatrics recommends children ... -- even 100 percent fruit juice -- each day. In ... on Children,s Health, however, it was found that about 50 ...
    ... c-MET expression in tumors., Invasion and metastasis were blocked ... are in late-stage clinical trials. PHILADELPHIA ... signaling inhibited tumor invasion and metastasis in a laboratory ... published in Cancer Discovery , the newest journal ...
    ... HealthDay Reporter , THURSDAY, Feb. 23 (HealthDay News) -- ... in overweight and obese women as those of normal ... females, a group of reproductive experts said. During ... Federation of America and the Society of Family Planning, ...
    ... generate a lot of internal debris that can trigger the ... as lupus., Now Georgia Health Sciences University researchers report that ... from attacking a fetus also helps block development of these ... joints. , The findings point toward new treatment strategies ...
    ... THURSDAY, Feb. 23 (HealthDay News) Compared to other ... in elderly patients with dementia, a new study finds. ... in dementia care. "This data provides much-needed guidance and ... treating older demented patients," said Dr. Gisele Wolf-Klein, director ...
    Cached Medicine News:Health News:Statins linked with lower depression risk in heart patients 2Health News:Kids From Poorer Families Drink Too Much Juice: Poll 2Health News:Combined inhibition of VEGF and c-MET can decrease metastasis 2Health News:Contraceptives Work Well in Obese Women, But Hormone Levels Lower 2Health News:Contraceptives Work Well in Obese Women, But Hormone Levels Lower 3Health News:Natural method for clearing cellular debris provides new targets for lupus treatment 2Health News:Natural method for clearing cellular debris provides new targets for lupus treatment 3Health News:Certain Antipsychotics Up Risk of Death for Patients With Dementia: Study 2
    ... Established in 1939, AMT has become ... agencies for clinical laboratory practitioners and ... certification for Medical Technologists, Medical Laboratory ... Phlebotomy Technicians, Medical and Dental Assistants ...
    ... Proficiency Testing and Quality Assurance (for Waived ... assist POLs, clinics and small hospitals maintain ... accuracy of patient lab results and assist ... the opportunity to earn 12 P.A.C.E. Contact ...
    An enzyme linked immunosorbent assay (ELISA) for the detection and quantitationof RF IgG isotype in human serum of patients with rheumatoid arthritis....
    An enzyme linked immunoassay (ELISA) for the detection and semiquantitationof IgG and IgM antibodies to 2-GP1, as an aid in assessingthe risk of thrombosis in patients with Systemic Lupus Erythematos...
    Medicine Products: